Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price objective reduced by equities researchers at Evercore ISI from $605.00 to $445.00 in a research note issued on Thursday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Evercore ISI’s price target suggests a potential upside of 13.64% from the company’s current price.
Other analysts also recently issued reports about the stock. UBS AG reaffirmed a “buy” rating and issued a $535.00 price objective (up from $489.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 4th. Citigroup Inc. upped their price objective on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a report on Friday, August 4th. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Bank of America Corporation reaffirmed a “buy” rating and issued a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $475.34.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $3.10 during mid-day trading on Thursday, hitting $391.59. 669,073 shares of the stock traded hands, compared to its average volume of 882,577. The stock has a market cap of $42,070.00, a P/E ratio of 33.32, a P/E/G ratio of 1.51 and a beta of 1.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a fifty-two week low of $340.09 and a fifty-two week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.13 EPS. equities analysts forecast that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) PT Lowered to $445.00” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/18/regeneron-pharmaceuticals-inc-regn-pt-lowered-to-445-00.html.
In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sanofi bought 166,415 shares of the stock in a transaction on Thursday, August 24th. The shares were bought at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold 61,460 shares of company stock valued at $29,143,390 in the last three months. 10.80% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in the business. FMR LLC boosted its stake in Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. boosted its stake in Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares during the period. Vanguard Group Inc. boosted its stake in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the period. Harding Loevner LP boosted its stake in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after buying an additional 3,131,966 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares during the period. 67.80% of the stock is owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.